If you choose a hereditary-cancer test that reads dozens of genes instead of two, you are more likely to come away with a variant of uncertain significance — a VUS. This is not a sign that anything is wrong with you, and it is not a flaw in the lab. It is a predictable consequence of arithmetic: every additional gene a panel reads is another stretch of DNA where a so-far-unexplained spelling difference can turn up. This explainer walks through why that happens, what the numbers actually look like, and how to read a VUS without alarm.
What a VUS is
When a laboratory finds a change in your DNA, it sorts that change into one of five tiers defined by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP, 2015):
- Pathogenic — strong evidence it is disease-causing
- Likely pathogenic — greater than ~90% certainty it is disease-causing
- Uncertain significance (VUS) — not enough evidence to call either way
- Likely benign — greater than ~90% certainty it is harmless
- Benign — strong evidence it is harmless
A VUS sits in the middle on purpose. It means the lab saw a real change — say, a substitution in BRCA2 or ATM — but the published population data, computational predictions, and family-history evidence don’t yet add up to a confident verdict. Clinical guidelines (NCCN and others) are explicit that a VUS should not be used to change your medical management. It is a placeholder, not a result.
Why more genes means more uncertainty
Think of each gene as a chapter of a very long book. In any chapter, most readers’ copies match the reference text, but a few carry odd spellings the editors haven’t yet ruled “typo” or “valid regional variant.” Read two chapters and you’ll meet few oddities. Read two hundred and you are almost guaranteed to find several.
The clinical data bear this out. In a large multi-gene-panel analysis, the rate of reports carrying a VUS rose steadily with panel size — roughly 6% for small panels of 2–10 genes, climbing to about 76% for panels of more than 200 genes. A focused study of breast- and ovarian-cancer testing showed the same gradient in miniature: testing BRCA1 and BRCA2 alone gave a VUS rate near 6%, adding fewer than ten more genes pushed it to about 14%, and adding more than ten genes raised it to roughly 32%.
| Test scope | Approx. chance of a VUS |
|---|---|
BRCA1 + BRCA2 only | ~6% |
| + <10 additional genes | ~14% |
| + >10 additional genes | ~32% |
| Large panel (>200 genes) | up to ~76% |
The pathogenic findings that change care tend to cluster in a handful of well-studied genes. The added genes on a big panel contribute relatively few actionable answers but plenty of extra chances for an uncertain one — so the VUS column grows faster than the answer column.
A VUS is usually temporary
The reassuring part is that uncertainty fades. As reference databases grow and labs re-evaluate old calls, most VUS are eventually reclassified — and the large majority move toward harmless. Across studies, when a VUS is reclassified it is downgraded to benign or likely benign roughly 80–92% of the time. In one breast-cancer cohort, about 20% of VUS were reclassified over the study period, and 92% of those moved to benign or likely benign. Reclassification can take years, which is why labs revisit variants periodically rather than all at once.
Why the odds aren’t the same for everyone
VUS rates are higher for people whose ancestry is underrepresented in genomic reference databases. Because the catalogues used to judge a variant were built disproportionately from European-ancestry data, a change common and harmless in another population may simply lack the evidence to be classified. In one analysis, individuals of Asian and Middle Eastern ancestry received an overall-VUS report about 35% and 33% of the time, versus roughly 17% for Ashkenazi Jewish and 20% for European ancestry. This is a database gap, not a difference in personal risk — and it narrows as more diverse data is shared.
A note on the PROMPT heritage
This registry desk takes its name from the PROMPT initiative — the Prospective Registry of Multiplex Testing — a real hereditary-cancer effort cited in ASCO’s Journal of Clinical Oncology that pooled multi-gene-panel results precisely to help resolve uncertain variants. PROMPT’s premise was that uncertainty shrinks when data is shared widely, which is the same mechanism that turns today’s VUS into tomorrow’s benign call. We honour that history while noting the registry is referenced here for context, not as an active enrolment.
The bottom line
A bigger panel reads more DNA, and more DNA means more chances to find a change nobody can yet classify — so VUS odds rise with panel size, from a few percent on a focused test to most reports on the largest panels. A VUS is an unfinished sentence, not a diagnosis: it should not change your care, it is usually resolved toward benign over time, and its likelihood depends partly on how well your ancestry is represented in shared databases. Knowing this in advance makes a VUS far easier to receive calmly.
Educational explainer, not medical advice. For your own testing or results, speak with a clinician or genetic counsellor.